Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc. Applied Therapeutics’ common stock is listed on the Nasdaq Global Market under the symbol “APLT.”

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. Its lead product candidate is a novel aldose reductase inhibitor with broad systemic exposure and peripheral nerve permeability that it is developing for the treatment of diabetic cardiomyopathy.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Alain Kuyumjian and associate Dmitriy Molchanov. Partner Michael Farber and associate Joseph M. Gerstel provided tax advice. The intellectual property and technology team included partner David R. Bauer and associate Yifu Chen. Counsel Loyti Cheng provided environmental advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post